ClinicalTrials.gg
RecruitingNCT06882772BASICS-KidsUpdated Oct 30, 2026

Butyric Acid Supplementation for Gut Improvement After Cardiac Surgery in Kids

A Phase 1/2 interventional study of 2 mL SunButyrate-TG and Placebo in Congenital Heart Disease (CHD), sponsored by University of Nebraska. Recruiting at 1 site in United States. Open to participants aged 1 Month to 3 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by University of Nebraska · Phase 1/2, Interventional, and Other

How we know

Updated Oct 30, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
1 Month to 3 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 356 studies in Heart Defects, Congenital with a site in United States — 67 open to participants now, 87 under way, 4 of them phase 3. Heart Defects, Congenital · United States.

Planned enrollment
48th of 184
105 · median 48
Started
2026
with 14 others
Phase 1/2
8 of 356
2 open now
Primary completion
2029-06
later than 71 of 86 live
Registered
336th of 356
by date

Among the 356 studies in Heart Defects, Congenital with a site in United States, this one is the 48th largest by planned enrollment of the 184 interventional ones that give a count, is one of 15 that started in 2026, is one of 8 in phase 1/2, reaches primary completion later than 71 of the 86 other live ones, and was the 336th registered.

Heart Defects, Congenital

992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.

Browse Heart Defects, Congenital studies →

Open to participants now

67 of the 356 studies in Heart Defects, Congenital with a site in United States are open now. Recruiting first, the newest first:

61 more — sign in →

All 67 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.

This study: 1 Month to 3 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 356 studies in Heart Defects, Congenital with a site in United States, or all of them as a file.
02

Study summary

Butyric acid has been shown to promote gut health and improve the microbiome in multiple adult studies. In preliminary studies in older children with inflammatory bowel disease, butyric acid was shown to be safe. However, it's suitability for infants and young children with congenital heart disease (CHD) has yet to be determined.

This study will examine butyric acid supplementation in infants and children, ages 1 month to 3 years, with CHD who require cardiac surgery with cardiopulmonary bypass. Study goals include determining the safety and tolerability of butyric acid supplementation before cardiac surgery, and to identify changes in gut microbial communities, metabolic profile, and genetic markers intestinal function. Also, the study seeks to establish a reduction in inflammation (inflammatory signaling) after cardiopulmonary bypass (CPB) in participants receiving butyric acid.

Read the detailed description

The goal of this study is to supplement a liquid form of butyric acid once daily for 3 weeks prior to cardiac surgery for infants and children, ages 1 month to 3 years, with congenital heart disease to improve their pre-operative gut microbiome in efforts to reduce post-operative gut permeability and reduce post-operative inflammatory signaling.

Up to 35 participants will be enrolled in each of three arms:

  • 2 mL butyric acid
  • 4 mL butyric acid
  • Placebo.

Participants will be asked to:

  • Provide blood and stool samples (baseline, post-supplement-pre-operative, 1-hr post-op, \& post-op days 1-3)
  • Take either 2 mL, 4 mL or placebo once daily for 3 weeks prior to cardiac surgery
  • Complete a daily log to track timing of supplement administration and any side effects or adverse events experienced

Study aims:

  • Aim 1 Safety and tolerability will be measured following baseline complete blood counts, complete metabolic panel to evaluate electrolytes and organ function, along with a daily log of supplementation timing and any experienced adverse events.
  • Aim 2 Modulation of gut health will be measured with stool and blood samples. Changes will be measured in the gut microbiome and metabolite profiles before and after supplementation, as well as post-operatively. Gut health will be determined by measuring plasma markers of gut barrier function before and after supplementation, as well as post-operatively.
  • Aim 3 Reduction of post-operative inflammatory signaling will be measured with blood samples. Plasma cytokine levels, immune cell profiles, and inflammatory gene activation with an RNA hybridization panel will be measured pre-operatively and post-operatively.
03

Conditions studied

  • Congenital Heart Disease (CHD)

Keywords

  • Congenital Heart Disease
  • Gut Health
  • Microbiome
  • Gut Barrier Function
  • Inflammation
04

Who can participate

Ages eligible
1 Month to 3 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infants and Children undergoing cardiac surgery with cardiopulmonary bypass

Exclusion criteria

Exclusion Criteria:

  • Antibiotics, surgery, or chemotherapy within the past 8 weeks
  • Continuous enteral feeds before surgery
  • GI pathology or intestinal surgery (excluding G-tube)
  • Liver disease with elevated transaminitis or dialysis-dependent renal disease
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
105 participants (estimated)

Study arms

  • Experimental
    2 mL SunButyrate-TG (Arm1)

    Participants will receive 2 milliliter (mL) SunButyrate-TG once daily for 3 weeks prior to cardiac surgery.

    Drug: 2 mL SunButyrate-TG

  • Experimental
    4 mL SunButyrate-TG (Arm 2)

    Participants will receive 4 milliliter (mL) SunButyrate-TG once daily for 3 weeks prior to cardiac surgery.

    Drug: 4 mL SunButyrate-TG

  • Placebo comparator
    Placebo Comparator (Arm 3)

    Participants will receive either 2 milliliter (mL) or 4 mL of an inactive oil-based placebo once daily for 3 weeks prior to cardiac surgery.

    Drug: Placebo

Interventions

  • Drug2 mL SunButyrate-TG

    Participants randomized into the 2 milliliter (mL) SunButyrate-TG will take the supplement once daily for 3 weeks prior to cardiac surgery. Note: This is a Dietary Supplement, but the FDA requires an Investigational New Drug (IND) number because inflammation is being treated.

    Also known as: Butyrate Liquid Supplement

  • DrugPlacebo

    Participants randomized into the Placebo arm will take the oil-based placebo once daily for 3 weeks prior to cardiac surgery

    Also known as: sugar pill

  • Drug4 mL SunButyrate-TG

    Participants randomized into the 4 mL SunButyrate-TG arm will take the supplement once daily for 3 weeks prior to cardiac surgery. Note: This is a Dietary Supplement, but the FDA requires an Investigational New Drug (IND) number because inflammation is being treated.

    Also known as: Butyrate Liquid Supplement

06

What researchers measure

Primary outcomes

  1. Combined Incidence of Adverse Events and Serious Adverse Events with Butyric Acid (SunButyrate-TG) Supplementation

    Safety will be measured by the combined incidence of adverse events (AE) and serious adverse events (SAE). These include allergic reaction, vomiting, diarrhea, abdominal distention, infection, hospitalization, or any other concern the families report. A Data Safety Monitoring Board (DSMB) will review and catalog the incidence and severity to determine study continuation. Investigators will evaluate each AE/SAE to determine the safety of the supplement in this age and participant population. AE and SAE definitions used according to FDA regulations. A scoring system of 1-5 will be used to determine the severity of the AE after review by the DSMB. A cumulative score of 3 or greater will require cessation of the study for that individual. If an accumulation of 20 participants or more have a score \>3 the study will be stopped. If an accumulation of SAE (score of 5) in 8 or more participants, the study will be stopped.

    Time frame: 3 years

  2. Tolerance of SunButyrate-TG

    Tolerance will be measured by the incidence of nausea, inability to consume the supplement, or parental concern of intolerance. The tolerance scoring metric will be used to aggregate the listed criteria into a score for each participant. Each characteristic will receive a point. If a participant has a score of 2 or greater, it will be defined as intolerance. Participant study continuation will be discussed with the family in weekly calls during the supplementation period.

    Time frame: Baseline to 3 weeks

  3. Changes to White Blood Cell Count with SunButyrate-TG Supplementation

    Safety will be evaluated through measurement of the white blood cell (WBC) count of the complete blood cell (CBC) count. Investigators will evaluate changes between the pre- and post-supplementation period CBC looking at changes in WBC count to quantify the incidence of leukocytosis (WBC \> 15.0 x 10\^9/L) and leukopenia (WBC \< 6.0 x 10\^9/L) after completing the supplement and prior to the surgery. Any participant that has a WBC count higher or lower than the values stated above will be documented.

    Time frame: Baseline to 3 weeks

  4. Changes to Hematocrit with SunButyrate-TG

    Investigators will measure hematocrit between pre- and post-supplement time points to determine the effect of SunButyrate-TG. Investigators will evaluate changes between the pre- and post-supplementation period complete blood count (CBC) looking at changes in of anemia (hematocrit \< 29%) or polycythemia (hematocrit \> 45%) after completing the supplement and prior to the surgery. Any participant that has a hematocrit higher or lower than the values stated above will be documented.

    Time frame: Baseline to 3 weeks

  5. Changes in Platelets with SunButyrate-TG

    Safety will be evaluated through measurement of the white blood cell (WBC) count of the complete blood cell (CBC) count. Investigators will evaluate changes between the pre- and post-supplementation period complete blood count looking at changes in platelet (PLT) count to quantify the incidence of thrombocytopenia (PLT \< 30 x 10\^9/L) or thrombocythemia (PLT \> 750 x 10\^9/L). Any participant that has a PLT count higher or lower than the values stated above will be documented.

    Time frame: Baseline to 3 weeks

  6. Changes to Renal Function (BUN, Creatinine or urine output) with SunButyrate-TG

    Investigators will collect blood for a comprehensive metabolic panel before and after supplementation with SunButyrate-TG. Investigators will evaluate the changes in blood urea nitrogen (BUN) and Creatinine to determine evidence of renal impairment or acute kidney injury based upon Kidney Disease: Improving Global Outcomes (KDIGO) criteria (creatinine increase 1.5-1.9 times baseline or \>0.3 mg/dL increase), or urine output \< 0.5 mL/kg/h for 6-12 hours (excluding overnight for potty-trained children).

    Time frame: Baseline to 4 months

  7. Changes in Liver Function with SunButyrate-TG

    Investigators will collect blood and measure a comprehensive metabolic panel before and after supplementation for evidence of liver injury. Investigators will determine: 1. Presence of acidosis (pH\< 7.3) 2. Elevation of transaminitis (AST/ALT \> 3 x baseline) 3. Elevation in INR (\>2 if not on coumadin) 4. Elevation in Bilirubin (\>2 mg/dL) 5. Elevation in alkaline phosphatase (\> 2 x baseline) If a participant meets any one of the above criteria, this will be considered evidence of liver injury and reported.

    Time frame: Baseline to 4 months

  8. Improvement in Gut Microbiome as Measured by Alpha Diversity, Shannon Diversity Index and Simpson Diversity Index with SunButyrate-TG Supplementation

    Changes to the gut microbiome will be measured before and after supplementation, as well as post-operatively. Investigators will measure improvement in alpha diversity and the number of short-chain fatty acids (SCFA) producing bacterial populations. An improvement will be classified by an increase in alpha diversity of measurable OTU's by 12, Shannon diversity index (increase of 0.5), and Simpson diversity index (increase of 0.08), and specific number of SCFA producing organisms by 5 OTU's compared to the placebo group.

    Time frame: Baseline to 4 months

  9. Changes in Short-Chain Fatty Acids with SunButyrate-TG

    Investigators will measure metabolite profiles to evaluate the amount of short-chain fatty acids (SCFA) in the gut and plasma before and after supplementation with SunButyrate-TG. This will be classified by a statistically significant increase (p\<0.05) in a list of 8 different SCFA. A positive increase in SCFA production will be classified by at least 1 SCFA being significantly increased following supplementation with SunButyrate-TG compared to the placebo group.

    Time frame: Baseline to 4 months

  10. Gut Barrier Function after SunButyrate-TG

    Investigators will measure 3 plasma markers of intestinal barrier function between pre- and post-supplement, as well as post-operatively. These markers are claudin-2, claudin-3, and intestinal fatty acid binding protein (FABP2). An improvement in gut barrier will be considered if there is a statistically significant reduction in the plasma marker of any of these at the post-supplementation, or post-operative time points compared to the placebo group.

    Time frame: Baseline to 4 months

Secondary outcomes

  1. Reduction of Post-Operative Cytokine Values

    Investigators will measure cytokine levels pre- and post-surgery to determine changes in cytokine profiles of a panel of 8 different cytokines, including TNF-alpha, IL-1, IL-4, IL-6, IL-7, IL-8, IL-10, TGF-beta and IFN-gamma). An improvement in the cytokine profile will be considered if there is a statistically significant reduction in pro-inflammatory cytokines (IL-1, TNFa, IL-6, IL-4, or IL-8, IFN-gamma) or a significant increase in anti-inflammatory cytokines (IL-10 and TGF-beta) compared to the placebo group. These cytokines are measured together and will be considered a positive improvement in cytokine profiles if at least 2 pro-inflammatory cytokine values are reduced in conjunction with an increase in IL-10 and/or TGF-beta.

    Time frame: Pre-surgery to 4 days post-operatively

  2. Changes in Neutrophils After Surgery with SunButyrate-TG

    Investigators will evaluate immune cell profiles in participants before and after surgery. Investigators will evaluate shifts in neutrophils. A significant change will be considered if there is a reduction of greater than 5% total neutrophil count via flow cytometry.

    Time frame: Pre-surgery to 4 days post-operatively

  3. Changes in Macrophages After Surgery with SunButyrate-TG

    Investigators will evaluate immune cell profiles in participants before and after surgery. Investigators will evaluate shifts in macrophages. A significant change will be considered if there is a reduction of greater than 5% total macrophage count via flow cytometry.

    Time frame: Pre-surgery to 4 days post-operatively

  4. Changes in T-regulatory Cells After Surgery with SunButyrate-TG

    Investigators will evaluate immune cell profiles in participants before and after surgery. Investigators will evaluate shifts in T-regulatory cells (T-cell). A significant change will be considered if there is an increase of greater than 10% in T-regulatory cell count via flow cytometry.

    Time frame: Pre-surgery to 4 days post-operatively

  5. Changes in Natural Killer T-cells Cells After Surgery with SunButyrate-TG

    Investigators will evaluate immune cell profiles in participants before and after surgery. Investigators will evaluate shifts in natural killer T-cells (NK T-cell). A significant change will be considered if there is a reduction of greater than 10% total NK T-cell count via flow cytometry.

    Time frame: Pre-surgery to 4 days post-operatively

Other outcomes

  1. Changes in Inflammatory Gene Activation

    Investigators will measure inflammatory genes using an ribonucleic acid (RNA) hybridization panel and evaluate the level of activation of these genes pre-and post-surgery to determine a decrease in inflammatory signaling following supplementation with SunButyrate-TG compared to placebo. These inflammatory gene profiles are identified as a panel are are unable to be separated out. The entirety of the inflammatory gene profile will be evaluated together to assess changes in inflammatory gene activation.

    Time frame: Pre-surgery to 4 days post-operatively

07

Study locations

1 of 1 sites recruiting
  • Children's Nebraska, 8200 Dodge St
    Omaha, Nebraska 68114, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Participant information will be partially de-identified. Information related to age, gender, ethnicity, and cardiac lesion will be shared. Additional information regarding the cardiac surgery, Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery (STAT) category, and lab values will also be included.

Supporting information: Study protocol, Clinical study report

Time frame: Information will be shared after completion of the study starting in 2029 and be available for 5 years.

Access criteria: Information will be shared upon request to the PI.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for Jun 2029, 31 months later.

Start moved once since we started tracking on Sep 25, 2026: Mar 2026 → Nov 2026, on Oct 30, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2025
First posted
Mar 19, 2025
StartEst.
Nov 1, 2026was Mar 2026
Primary completionEst.
Jun 30, 2029
CompletionEst.
Dec 31, 2029
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 30, 2026
Sites
Children's Nebraska, 8200 Dodge St is now Recruiting
Oct 30, 2026
Start date
Mar 2026→Nov 1, 2026
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Not yet recruiting→Recruiting
    Children's Nebraska, 8200 Dodge St is now Recruiting
    Start date Mar 2026→Nov 1, 2026
    + 3 other changes: verification date, registry dates and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06882772
Responsible party
Jeffrey Salomon (Associate Professor, University of Nebraska) — Principal investigator
First posted
Mar 19, 2025
Start date
Nov 1, 2026 (estimated)
Primary completion
Jun 30, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Oct 30, 2026

Study contacts

Jeffrey D Salomon, MD, MBA
Contact
jeffrey.salomon@unmc.edu
940-453-7166
Jeffrey Salomon, MD, MBA
principal investigator · University of Nebraska

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion